PNNL

Abstract

The purpose of this study was to examine the therapeutic efficacy of 188Re-(Arg11)CCMSH in the B16/F1 murine melanoma and TXM13 human melanoma bearing mouse models. Method: (Arg11)CCMSH was synthesized and labeled with 188Re to form 188Re-(Agr11)CCMSH. B16/F1 melanoma tumor bearing mice were administrated with 200 µCi, 600 µCi and 2x400 µCi of 188Re-(Arg11)CCMSH via the tail vein, respectively. TXM13 melanoma tumor hearing mice were separately injected with 600 µCi, 2x400 µCi and 1000 µCi of 100Re-(Arg11)CCMSH through the tail vein. Two groups of 10 mice bearing either B16/F1 or TXM13 tumors were injected with saline as untreated controls. Results: In contrast to the untreated control group, 188Re(Arg11)CCMSH yielded rapid and lasting therapeutic effects in the treatment groups with either B16/F1 or TXM13 tumors. The tumor grouth rate was reduced and the survival rate was prolonged in the treatment groups. Treatment with 2x400 µCi of 188Re-Arg11)CCMSH significantly extended the mean life of B16/F1 tumor mice (p